Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.597453
Keywords
pegylated liposomal doxorubicin; multiple myeloma; efficacy; survival; toxicity
Categories
Funding
- National Natural Science Foundation of China [82070203, 81800194, 81770210, 81473486, 81270598]
- Key Research and Development Program of Shandong Province [2018CXGC1213]
- Shandong Provincial Natural Science Foundation [ZR2018BH011]
- Development Project of Youth Innovation Teams in Colleges and Universities of Shandong Province [2020KJL006]
- China Postdoctoral Science Foundation [2020M672103]
- Technology Development Projects of Shandong Province [2017GSF18189]
- Translational Research Grant of NCRCH [2021WWB02, 2020ZKMB01]
- Technology Development Project of Jinan City [201805065]
- Taishan Scholars Program of Shandong Province
- Academic promotion programme of Shandong First Medical University [2019QL018, 2020RC006]
- Shandong Provincial Engineering Research Center of Lymphoma
Ask authors/readers for more resources
The study found that in bortezomib-containing regimens, VDD had significantly higher complete response rate and very good partial response rate compared to VD subgroup. There was no significant difference in survival between VDD and VD subgroups. In vindesine-containing regimens, there was no statistical significance between vDD and vAD in terms of response rate, survival, and toxicity.
Purpose Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined. Methods A total of 249 NDMM patients diagnosed between January 2008 and October 2019 were included in this retrospective study. Among them, 112 patients received vindesine-based chemotherapy (35 vDD and 77 vAD) and 137 received bortezomib-based chemotherapy (58 VDD and 79 VD). Results In bortezomib-containing regimens, the complete response rate (48.3 vs. 30.4%, p = 0.033) and very good partial response or better rate (74.1 vs. 57.0%, p = 0.038) of VDD were significantly higher than those of VD subgroup. While no superior survival was found between VDD and VD subgroup. In vindesine-containing regimens, no statistical significance was identified between vDD and vAD in terms of response rate and survival. The occurrence rates of all cardiac AEs were similar between VDD and VD. Conclusions The vDD regimen was similar with vAD in the aspect of response rate, survival, and toxicity in NDMM patients. The addition of PLD to VD brought deeper response without increased toxicity, while no superior survival was found.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available